David LLorente

🔬 $1M to $4M in CRO fees alone for a Phase I trial. Much of it goes to infrastructure, not data. The CRO model is being pushed to evolve and agentic AI enables faster execution. Not bigger teams. Smarter systems. See how 👇 narrativa.com/agentic-ai-cro…

Excited to see this podcast come to life!! Congratulations, Jennifer. This series does a great job of breaking down what actually matters and what is worth your time. ⤵️

We know a thing or two about AI, and we have applied that experience to build the AI Confidence Training Program. If AI still feels confusing or overwhelming, start here. 👇

Huge congratulations, Jennifer!! Very well-deserved recognition of your work in life sciences.

TechBio AI valuations, hype or real? For companies using AI to make clinical development cheaper and faster, it looks a lot less like hype. They are front-loading success - especially from Phase I to II, where most capital gets incinerated. >PhI to II success jumps to ~80% (~40-65% historic) >PhII still hard, but meaningfully better than baseline >Later stages show smaller deltas, as expected While we often value companies off peak sales and lifetime revenue, is not only about peak sales. How much capital and time you spend to find out if something works matters as well. AI helps: >pick better targets, >run tighter trials, >kill bad programs faster, >reach POC sooner, Then you cut burn, shorten timelines, and improve capital recycling = higher rNPV and IRR!!!! So who buys one of these AI clinical efficiency enhancement stories? >mid-cap pharma that needs pipeline but cannot afford repeated Phase II misses >big pharma BD looking for de-risked assets with cleaner early data >platform acquirers who want a repeatable engine, not a one-off drug >strategics facing patent cliffs, where speed matters 🤔The question is do one of the buyers above make a traditional M&A bid? Or do they wind up signing lucrative collaboration or subscription models and the ultimate buyer is one of the tech health divisions (think Google, OpenAI, Meta, etc) that can integrate the backend data and use it to further drive enhancement? biospace.com/drug-developme…

If you are heading to Orlando for #SCOPE2026, send Jennifer Bittinger a message to set up a quick chat. ⬇️

🔮 2026 is here and AI in Pharma is moving fast. Less hype, more focus on what actually scales: AI agents, verticalization, and real ROI. Here is what our AI experts at Narrativa see coming. 👇 #AIinPharma #LifeSciences #AgenticAI narrativa.com/ai-trends-in-p…

@NarrativaAI Agentic AI is making a real difference for regulatory teams, and this is just the beginning. Let’s see what agentic AI delivers in 2026. 👏

🧬 How did agentic AI impact our clients in 2025? ✔️ 65,000+ regulatory documents ✔️ 76% faster analysis and narrative creation ✔️ 50% higher team productivity ✔️ 43% lower project costs This is what agentic AI looks like in production. 🔗 Read more: narrativa.com/delivering-650…

Happy to connect during J.P. Morgan Healthcare Week in San Francisco. Please feel free to reach out. 📩

Lisa is absolutely right. We talk a lot about metrics, but what really matters are those moments when a patient reaches a potential cure.

@NarrativaAI In pharma and biotech, you simply can’t take risks. Any move toward clearer guidance in AI is worth watching.

🌍 What is ISO 42001 and why does it matter for AI? ISO 42001 is here to keep AI on its best behavior, and this is especially important in life sciences, where data privacy, accuracy, and trust are critical. 👉 Read the full post to learn more. narrativa.com/what-is-iso-42…

@NarrativaAI Welcome aboard! We are happy to have you.

🧬 We’re excited to welcome Samantha Eells to Narrativa as our new Key Account Manager. Samantha is an innovative epidemiologist with 20 years of experience in life sciences. Welcome to the team! Get to know her better 👉 narrativa.com/narrativa-welc… #TeamNarrativa #LifeSciences

✍️ Not everything you read is written by AI. Or is it? In 2024, AI-generated articles temporarily surpassed human ones, according to Graphite.io. But the future isn’t AI or human: it’s human + AI. Discover more insights here. 👇 narrativa.com/not-everything…

Few people know the pharmaceutical industry like David Evans. His experience working closely with regulators gives him a unique perspective, and it’s a pleasure listening to him share it.

Proud of what we’ve accomplished, but even more excited for what’s ahead. Not every year a company turns 10, and the secret is simple: surround yourself with a great team. Thank you to everyone who’s been part of the journey!

Our main goal is to make content creation easier, faster, and more consistent for every team. The features of Narrativa® Navigator make that possible, and open the door to much more.

They’re both Argentinian media outlets, already strong in their home market. Now, Infobae and El Cronista lead the media rankings in Mexico. With Narrativa® Navigator, they’ve expanded to new markets—faster and without losing quality. Congratulations to both teams!

Many of our clients ask us whether it’s better to host their own LLM or use a managed solution. It’s an important choice that affects privacy, control, cost, and speed, so we’ve put together this simple guide to help clarify the pros and cons. Hope it’s helpful!

It was a pleasure to be part of the conversation and share @NarrativaAI’s story.

🗃️ Everyone’s hyped about #GenerativeAI… but structured data is doing the real heavy lifting. No clean data? No clean content. 🪄 If your AI is working with messy spreadsheets or PDFs from 2009… don't expect magic! Read before you hit "generate"⤵️ narrativa.com/what-is-struct…